The counsel appearing for the state said it was aggrieved by some comments made in the high court order.
Bihar Chief Minister Nitish Kumar on Monday said that Bollywood actor Aamir Khan is welcome in the state to create awareness and popularise generic drugs among people.
Turbo finds its footing in the latter half with some well-conceived one-upmanship between hero and villain, yet it's marred by poorly executed action set pieces in the climactic showdown.
The company's US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market after having received approval to market it from the US Food and Drug Administration, according to a statement by Lupin.
The non-branded generic drugs (sold under chemical names such as cetrizene, omeprazole and nimusulide), which constitute about 8 per cent of the Rs 30,000 crore (Rs 300 billion) Indian pharmaceutical market, is currently not subjected to any such margin cap and according to a study done by the department some of them such are even sold at a margin as high as 1,000 per cent in the market.
In a release issued on February 13, FTC alleged that Cephalon's 'anti-competitive' scheme denies patients access to lower cost, generic versions of Provigil (modafinil) and forces consumers and other purchasers to pay hundreds of millions of dollars a year more for Provigil.
Independence Day was celebrated across states and Union territories on Thursday, as several chief ministers announced job schemes while some others vowed their support for Prime Minister Narendra Modi's vision of a Viksit Bharat by 2047.
As India's drug majors in this segment increasingly trip on American standards, increasing the scrutiny on their practices, their counterparts look up there.
The west is faced with a daunting task on patent expiry, increasing challenges from generics, pipeline showing limited blockbusters, and in addition to that increasing pricing pressure.
After being raided by Federal officials, Ranbaxy Laboratories Ltd, India's largest pharmaceutical company, has been taken to court in the US by a consumer health group that supports the sale of low-priced generic medicines.
The increasing number of generic players tapping the US market for known molecules has resulted in pricing pressures and lean margins.
'That is a significant milestone for us and something we aspired for.'
But analysts see this as an encouraging shift of stance on part of Indian pharma companies that have so far been dependent on the patents challenge route.
A strong performance in the July-September quarter of 2023-24 (Q2FY24), an upward revision in the margin guidance and sustained momentum in US sales has helped the stock of pharmaceutical major Cipla gain about 2 per cent over the last two trading sessions. The brokerages have upgraded the earnings estimates for this financial year (FY24) by 6-9 per cent to factor in the improved margin guidance and sales in the US market. Led by the US market, which rose by 31 per cent, the company posted a 16 per cent growth in revenues.
'The Railways decided to go for kavach three years back, but the progress has been very slow.'
Sun Pharmaceutical Industries reported a 34 per cent year-on-year (Y-o-Y) jump in net profit to Rs 2,654.6 crore in Q4FY24.
The Wall Street Journal has reported that the SEC has contacted many investment banks whose analysts cover generic drug-maker Mylan, asking about a meeting the company hosted last September with those analysts and a group of investors.
The United States Food and Drug Administration on Tuesday banned the import of more than 30 generic drugs manufactured by Ranbaxy Laboratories Limited alleging that poor quality control at the firm's factories could be harmful to users of these medications used to treat everything from high cholesterol to Type 2 diabetes to everyday allergies.
Germany's drug regulator has banned the sale of 80 generic medicines with immediate effect on the grounds that their clinical trials conducted by India's pharmaceutical research company GVK Biosciences were "insufficient".
Training modules also cover academic courses, Gaganyaan flight systems, nicro-gravity familiarisation through parabolic flights, recovery training, mastering of flight procedures and training on crew training simulators, according to ISRO sources.
Guntu Kaaram doesn't deliver on its basic promise: Entertainment, sighs Mayur Sanap.
Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said it expected to get US approvals for a paediatric dosage of its generic version of Augmentin, GlaxoSmithKline's blockbuster antibiotic, within a month.\n\n\n\n
Hyderabad-based pharma company Dr Reddy's Laboratories (DRL) has acquired Jet Generici Srl, a company engaged in the sale of generic finished dosages in Italy. Financial terms and conditions of the transaction were not disclosed. The deal has been completed through Dr Reddy's Italian subsidiary, Reddy Pharma Italia, which has been engaged in building a pipeline of registrations since its incorporation.
.jpg)
The company has launched the Decitabine for injection in the strength of 50 mg in the US market following approval by the United States Food & Drug Administration of Dr Reddy's abbreviated new drug applications, it said in a statement.
A recent court ruling in the US on allowing the declaratory judgment provision in the US patent law has come as a boost to Indian pharmaceutical companies such as Ranbaxy, Dr Reddy's, Sun Pharma and Lupin.
Pharma company Wanbury Ltd on Monday said it will acquire the branded generic business of Spain-based Industrial Farmaceutica Cantabria through Cantabria Pharma SL for 50 million Euro.
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
They seek to profit from big-selling drugs going off-patent this year in the lucrative market.
Pharmexcil had recently taken a 25-member delegation to Iran in order to promote pharma trade with the Western Asia nation.
Operating margins have been the primary driver of corporate earnings in India in recent quarters, despite revenue growth suffering from weak consumer demand. Companies across sectors have reported a sharp improvement in earnings before interest, tax, depreciation, and amortisation (Ebitda) margins over the past two years, benefiting from lower commodity and energy prices. Higher margins more than compensated for slower revenue growth, resulting in double-digit growth in net profit for five consecutive quarters.
Leading Indian pharmaceutical company Ranbaxy Laboratories Limited has offered to provide oseltamivir phosphate capsules
Sangwan said he made the generic remark on his YouTube channel and not during his lecture at Unacademy.
Pfizer Inc and Ranbaxy Laboratories Ltd on Friday won dismissal of a U.S. antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the best-selling cholesterol drug Lipitor.
Sales growth of generics drugs has dropped to 3.6 per cent in the 12 months ended September 2008 compared with 11.4 per cent growth a year earlier, according to the latest report of IMS Health, the leading provider of market intelligence to the global pharmaceutical and healthcare industries. However, sales by volume increased by 5.4 per cent in the US, reflecting declining prices and fewer blockbusters losing patent protection in 2008.
Aurobindo Pharma has acquired business assets of the UK-based generic drug maker Milpharm.
The drug had generated sales of $600 million in the first six months of its launch in the US, as Ranbaxy had exclusive marketing rights for it.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances